Recombinant vaccinia virus expressing the middle hepatitis B virus surface antigen was incapable of inducing marked antibody response against the S and pre-S2 antigenic specifities in mice. However, mice immunized with this virus produced antibodies to both these antigens after the following administration of subtreshold doses of plasmatic hepatitis B surface antigen.

Department of Experimental Virology Institute of Sera and Vaccines Prague Czechoslovakia

See more in PubMed

Science. 1985 Jun 7;228(4704):1195-9 PubMed

J Virol. 1987 Apr;61(4):1286-90 PubMed

J Virol. 1984 Mar;49(3):857-64 PubMed

Acta Virol. 1969 May;13(3):209-15 PubMed

Virology. 1962 Sep;18:9-18 PubMed

Virology. 1981 Aug;113(1):408-11 PubMed

Arch Virol. 1990;112(3-4):181-93 PubMed

Immunol Res. 1987;6(1-2):80-100 PubMed

Vaccine. 1988 Aug;6(4):357-61 PubMed

J Virol. 1982 Apr;42(1):100-5 PubMed

J Med Virol. 1986 Oct;20(2):111-25 PubMed

Nature. 1984 Sep 6-11;311(5981):67-9 PubMed

Immunol Today. 1987;8(9):270-3 PubMed

Attenuation of vaccinia virus by the expression of human Flt3 ligand

Hepatitis B virus proteins expressed by recombinant vaccinia viruses: influence of preS2 sequence on expression surface and nucleocapsid proteins in human diploid cells

Synthesis and immunogenicity of hepatitis B virus envelope antigen expressed by recombinant vaccinia virus. Finding of retention signal in the C-terminal portion of the preS1 domain of subtype adyw